Bromide

Bromide

SCHEMBL1775522

C=CC[N+](CC)(CC)CC/C=C1/c2ccccc2Sc2ccc(C)cc21.[Br-]

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 known ✓ P08172 1/20 0.42
CHRM1 known ✓ P11229 1/20 0.42
OPRM1 known ✓ P35372 1/20 0.42
HRH2 known ✓ P25021 1/20 0.35
MEN1 O00255 7/20 0.54
KMT2A Q03164 7/20 0.54
USP2 O75604 5/20 0.48
APAF1 O14727 2/20 0.48
POLB P06746 2/20 0.48
HSP90AA1 P07900 2/20 0.48
MC4R P32245 2/20 0.48
UBE2N P61088 2/20 0.48
RAD52 P43351 2/20 0.48
RCE1 Q9Y256 1/20 0.48
MAPT P10636 1/20 0.48
CYP3A4 P08684 6/20 0.42
LMNA P02545 5/20 0.42
CYP2D6 P10635 5/20 0.42
CYP1A2 P05177 4/20 0.42
CYP2C19 P33261 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1774760 1.00 MEN1 (0.54) MEN1KMT2AUSP2APAF1POLB
SCHEMBL12604824 0.99 MEN1 (0.53) MEN1KMT2AUSP2APAF1POLB
SCHEMBL3682878 0.90 MEN1 (0.59) MEN1KMT2AUSP2APAF1POLB
SCHEMBL3682876 0.90 MEN1 (0.59) MEN1KMT2AUSP2APAF1POLB
Iodide SCHEMBL1776353 0.89 MEN1 (0.58) MEN1KMT2AUSP2APAF1POLB
Iodide SCHEMBL1774916 0.89 MEN1 (0.58) MEN1KMT2AUSP2APAF1POLB
Bromide SCHEMBL1774747 0.87 MEN1 (0.59) MEN1KMT2AUSP2APAF1POLB
Bromide SCHEMBL1774748 0.87 MEN1 (0.59) MEN1KMT2AUSP2APAF1POLB
SCHEMBL12604822 0.85 MEN1 (0.57) MEN1KMT2AUSP2APAF1POLB
SCHEMBL12604821 0.82 MEN1 (0.61) MEN1KMT2AUSP2APAF1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943606-B2 Compositions and methods to control abnormal cell growth CANCURE LABORATORIES, LLC (US) 2011-05-17 US claimed
US-20100215635-A1 SMALL MOLECULES TO INDUCE WEIGHT LOSS OR TO REDUCE WEIGHT GAIN KISS ZOLTAN 2010-08-26 US claimed
US-7781423-B2 Compounds to promote regeneration of bone marrow CANCURE LABORATORIES, LLC (US) 2010-08-24 US claimed
US-20100048668-A1 COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH CANCURE LABORATORIES, LLC (US) 2010-02-25 US claimed
US-20100022617-A1 COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH CANCURE LABORATORIES, LLC (US) 2010-01-28 US claimed
US-20090317372-A1 SMALL MOLECULES FOR THE REDUCTION OF HIGH BLOOD GLUCOSE LEVEL KISS ZOLTAN 2009-12-24 US claimed
US-20090030066-A1 SMALL MOLECULES FOR THE PROTECTION OF PANCREATIC CELLS ZOLTAN LABORATORIES LLC (US) 2009-01-29 US claimed
US-20090004136-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW ZOLTAN LABORATORIES LLC (US) 2009-01-01 US claimed
WO-2008118164-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW ZOLTAN LABORATORIES LLC (US) 2008-10-02 WO claimed
US-20080234234-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW ZOLTAN LABORATORIES, LLC (US) 2008-09-25 US claimed
US-7423029-B1 from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts; e.g. [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride; antitumor and AIDS agent; low toxicity, side effect reduction ZOLTAN LABORATORIES, LLC (US) 2008-09-09 US claimed
US-7943606-B2 Compositions and methods to control abnormal cell growth CANCURE LABORATORIES, LLC (US) 2011-05-17 US disclosed
US-7943606-B2 Compositions and methods to control abnormal cell growth CANCURE LABORATORIES, LLC (US) 2011-05-17 US disclosed
US-20100215635-A1 SMALL MOLECULES TO INDUCE WEIGHT LOSS OR TO REDUCE WEIGHT GAIN KISS ZOLTAN 2010-08-26 US disclosed
US-7781423-B2 Compounds to promote regeneration of bone marrow CANCURE LABORATORIES, LLC (US) 2010-08-24 US disclosed
US-20090030066-A1 SMALL MOLECULES FOR THE PROTECTION OF PANCREATIC CELLS ZOLTAN LABORATORIES LLC (US) 2009-01-29 US disclosed
US-20090004136-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW ZOLTAN LABORATORIES LLC (US) 2009-01-01 US disclosed
US-20080234234-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW ZOLTAN LABORATORIES, LLC (US) 2008-09-25 US disclosed
US-7423029-B1 from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts; e.g. [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride; antitumor and AIDS agent; low toxicity, side effect reduction ZOLTAN LABORATORIES, LLC (US) 2008-09-09 US disclosed
US-20080207738-A1 DRUG COMBINATIONS TO TREAT DRUG RESISTANT TUMORS CANCURE LABORATORIES, LLC (US) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090004136-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW PDGFA, BMP4, BMP2 CHRM2 4566/4885CHRM1 4598/4885OPRM1 3575/4885
US-20090317372-A1 SMALL MOLECULES FOR THE REDUCTION OF HIGH BLOOD GLUCOSE LEVEL KCNN1, KCNN3, SLC2A9 CHRM2 3513/4885CHRM1 2728/4885OPRM1 3061/4885
US-20080207738-A1 DRUG COMBINATIONS TO TREAT DRUG RESISTANT TUMORS ABCC1, BRCA1, VHL CHRM2 4874/4885CHRM1 4838/4885OPRM1 1559/4885
US-20100215635-A1 SMALL MOLECULES TO INDUCE WEIGHT LOSS OR TO REDUCE WEIGHT GAIN GPR119, FABP4, PNLIP CHRM2 2656/4885CHRM1 3155/4885OPRM1 2012/4885
US-20100048668-A1 COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH ALPP, ALPG, MKI67 CHRM2 4465/4885CHRM1 4720/4885OPRM1 3345/4885
US-20090030066-A1 SMALL MOLECULES FOR THE PROTECTION OF PANCREATIC CELLS RNASE1, IAPP, POT1 CHRM2 3081/4885CHRM1 2499/4885OPRM1 1477/4885
US-20080234234-A1 COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW PDGFA, BMP4, BMP2 CHRM2 4566/4885CHRM1 4598/4885OPRM1 3575/4885
US-20100022617-A1 COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH ALPP, ALPG, DNTT CHRM2 4616/4885CHRM1 4758/4885OPRM1 4076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.